A dual-agonist formulation for weight care, targeting both GLP-1 and GIP receptor pathways as part of a clinically managed program
But the connection is when you look to their pathogenesis, or what is changing, similar mechanisms are changing
In this lower kidney risk cohort, dapagliflozin reduced the composite kidney endpoint, which included a more modest 40% decline in eGFR, ESKD or renal death, by 47% (HR, 0.53
Researchers have commented that the peptide appears to cause increases in mean plasma GH concentrations by 2- to 10-fold [...] and in mean plasma IGF-I concentrations by 1.5- to 3-fold... [2] CJC-1295 has been primarily researched for its potential in mitigating actions frequently associated with cell aging
Exercise has decades of evidence showing lower blood pressure, better cholesterol, and lower risk of death from all causes